Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - Pharmaceutical News - DelMar taps PRA Health Sciences to run pivotal brain cancer trial [Algeria Press Service] - October 19, 2017

Pharmacy News Article

 5/19/17 - DelMar taps PRA Health Sciences to run pivotal brain cancer trial [Algeria Press Service]

DelMar is advancing its first-in-class brain cancer med dianhydrogalactitol (VAL-083) into phase 3, and it has recruited PRA Health Sciences to conduct that pivotal study.

The phase 3 trial, slated to start in June, will test the chemotherapy in recurrent glioblastoma multiforme (GBM) patients who have failed standard Temodar-Avastin treatments, an area where no currently approved therapy exists.

VAL-083, DelMars lead candidate, demonstrated clinical activity against several cancers in previous clinical trials sponsored by the U.S. National Cancer Institute. It has already nabbed an orphan drug designation in Europe for gliomas, and it has also received orphan designations from the FDA for glioma, medulloblastoma and ovarian cancer.

DelMar had been working with PRA for "quite some time" in preparing for the trial before the pair formally joined up, DelMars chairman and CEO, Jeffrey Bacha, said in a statement. The new phase 3 trial will inherit the dosing regimen of 40 mg/m2/d on days one to three of a 21-day cycle, as determined in a phase 1/2 trial. The pair plans to enroll 180 patients and complete the study in August 2019.

Following guidance from the FDA, the Vancouver, Canada-based biopharma companywith the help of MD Anderson Cancer Centerstarted a phase 2 trial in January to test the drug in Avastin-nave first recurrent glioblastoma patients.

The company is also collaborating with Sun Yat-sen University in China to test the medication as a first-line brain cancer treatment in phase 2. That 30-subject study is expected to start in June.

About 66% of GBM tumors demonstrate high expression of the MGMT promoter gene, and through its repair mechanism, those tumors can grow resistant to Temodar. In previous studies, VAL-083 has shown to be unaffected by the expression of MGMT, thus bearing the potential to become a new treatment option for patients who might be poor responders to Temodar.

As for PRA, at the end of April, the North Carolina-based CRO posted near 15% revenue growth for the first quarter of 2017, and the $427.1 million haul outperformed Wall Streets previous expectations of a bit below $420 million. In addition, the company received new orders worth $564.8 million in that quarter.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 19: Type II Diabetes: Case Studies and Management Options
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement